Decentralization: A Direct Approach to Clinical Trials
Summary: Due to COVID-19 risks, local lockdowns, patient and site staff safety, and personal choice, some patients have been unable or unwilling to travel to their clinical site and in some cases, clinical sites have had to close completely. This new way of life provides an opportunity for the further decentralization of clinical trials, with direct-to-patient protocols reducing or eliminating the need for patients to travel to clinical sites and potentially expose themselves and others to a risk of infection.